Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib in Lower Risk MDS and CMML Without IDH2 Mutation
NCT05282459Phase 2Completed
- Sponsor
- Tianyi Zhang
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib in anemia, sponsored by Tianyi Zhang. Started Jan 2022; status: completed.
02
Drugs
enasidenib
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05282459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282459.